Judson M Englert
Overview
Explore the profile of Judson M Englert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
13
Citations
1134
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Oh M, Sun I, Zhao L, Leone R, Sun I, Xu W, et al.
J Clin Invest
. 2020 Apr;
130(7):3865-3884.
PMID: 32324593
Myeloid cells comprise a major component of the tumor microenvironment (TME) that promotes tumor growth and immune evasion. By employing a small-molecule inhibitor of glutamine metabolism, not only were we...
2.
Leone R, Zhao L, Englert J, Sun I, Oh M, Sun I, et al.
Science
. 2019 Nov;
366(6468):1013-1021.
PMID: 31699883
The metabolic characteristics of tumors present considerable hurdles to immune cell function and cancer immunotherapy. Using a glutamine antagonist, we metabolically dismantled the immunosuppressive microenvironment of tumors. We demonstrate that...
3.
Kelly R, Lee J, Bang Y, Almhanna K, Blum-Murphy M, Catenacci D, et al.
Clin Cancer Res
. 2019 Nov;
26(4):846-854.
PMID: 31676670
Purpose: This randomized, multicenter, open-label, phase Ib/II study assessed durvalumab and tremelimumab in combination or as monotherapy for chemotherapy-refractory gastric cancer or gastroesophageal junction (GEJ) cancer. Patients And Methods: Second-line...
4.
Englert J, Powell J
Cancer Cell
. 2016 Jul;
30(1):13-15.
PMID: 27411584
In this issue, Pietrocola et al. and Di Biase et al. independently demonstrate that caloric restriction from fasting and pharmacologic inhibition results in an enhanced immunogenic response leading to reduced...
5.
Milutinovic P, Englert J, Crum L, Mason N, Ramsgaard L, Enghild J, et al.
PLoS One
. 2014 Mar;
9(3):e88259.
PMID: 24642901
Elucidating the sites and mechanisms of sRAGE action in the healthy state is vital to better understand the biological importance of the receptor for advanced glycation end products (RAGE). Previous...
6.
Milutinovic P, Alcorn J, Englert J, Crum L, Oury T
Am J Pathol
. 2012 Aug;
181(4):1215-25.
PMID: 22889845
The receptor for advanced glycation end products (RAGE) is a multiligand receptor that has been shown to contribute to the pathogenesis of diabetes, atherosclerosis, and neurodegeneration. However, its role in...
7.
Ramsgaard L, Englert J, Manni M, Milutinovic P, Gefter J, Tobolewski J, et al.
PLoS One
. 2011 Jun;
6(5):e20132.
PMID: 21629785
Background: The receptor for advanced glycation end-products (RAGE) has been suggested to modulate lung injury in models of acute pulmonary inflammation. To study this further, model systems utilizing wild type...
8.
Kliment C, Englert J, Crum L, Oury T
Int J Clin Exp Pathol
. 2011 May;
4(4):349-55.
PMID: 21577320
Aim: The purpose of this study was to develop an improved method for collagen and protein assessment of fibrotic lungs while decreasing animal use. Methods: 8-10 week old, male C57BL/6...
9.
Englert J, Kliment C, Ramsgaard L, Milutinovic P, Crum L, Tobolewski J, et al.
Int J Clin Exp Pathol
. 2011 Apr;
4(3):241-54.
PMID: 21487520
Idiopathic pulmonary fibrosis (IPF) is a progressive disease with poor survival. The identification of therapeutic targets is essential to improving outcomes. Previous studies found that expression of the receptor for...
10.
Ramsgaard L, Englert J, Tobolewski J, Tomai L, Fattman C, Leme A, et al.
PLoS One
. 2010 Mar;
5(3):e9604.
PMID: 20333255
Background: The role of the receptor for advanced glycation end-products (RAGE) has been shown to differ in two different mouse models of asbestos and bleomycin induced pulmonary fibrosis. RAGE knockout...